3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
3
Withdrawn
1
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Multiple Myeloma
112
Recurrence
29
Precursor Cell Lymphoblastic Leukemia-Lymphoma
18
Neoplasms
14
Neoplasms, Plasma Cell
13
Leukemia
10
Lymphoma, Non-Hodgkin
8
Lymphoma
8
Leukemia, Myeloid, Acute
8
Carcinoma, Non-Small-Cell Lung
8
Lymphoma, Large B-Cell, Diffuse
7
Burkitt Lymphoma
7
Vomiting
6
Prostatic Neoplasms
6
Breast Neoplasms
6
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
5
Neoplasm Metastasis
5
Nausea
5
Lung Neoplasms
5
Pancreatic Neoplasms
3
Lymphoma, Follicular
3
Immunoglobulin Light-chain Amyloidosis
3
Hematologic Neoplasms
3
Hematologic Diseases
3
Glioblastoma
3
Amyloidosis
3
Smoldering Multiple Myeloma
2
Renal Insufficiency
2
Oligodendroglioma
2
Myelodysplastic Syndromes
2
Interventions
Carboplatin
25
Etoposide
23
Cisplatin
16
pembrolizumab
9
Topotecan
9
atezolizumab
7
Pemetrexed
7
Nivolumab
7
Radiosurgery
6
Irinotecan
5
durvalumab
4
Paclitaxel
4
Gemcitabine
4
Albumin-Bound Paclitaxel
4
rovalpituzumab tesirine
3
etoposide phosphate
3
Radiotherapy
3
Magnetic Resonance Spectroscopy
3
Ipilimumab
3
Cyclophosphamide
3
vistusertib
2
roniciclib
2
pelcitoclax
2
pazopanib
2
epacadostat
2
amrubicin
2
Vorinostat
2
Radiation
2
Fluorodeoxyglucose F18
2
Doxorubicin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Small Cell Lung Carcinoma
×
Dexamethasone
×
Clear all
NCT03033511
2021-07-29
MERU
AbbVie
Phase 3
Terminated
748 enrolled
13 charts